GlobeNewswire Inc.··Acumen Pharmaceuticals, Inc.Acumen Pharma Cuts R&D Costs as Alzheimer's Trial Nears Readout
Acumen Pharmaceuticals reported $128.4M cash reserves in Q1 2026, with Phase 2 Alzheimer's trial results expected late 2026 and R&D expenses down 35% year-over-year.
ABOSclinical trial resultsAlzheimer's disease